1. Menzies R, McIntyre P, Beard F. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 1999 to 2002. Commun Dis Intell 2004;28 Suppl 1:S1–S45.
2. Australian Institute of Health and Welfare. Improving the quality of Indigenous identification in hospital separations data. Australian Institute of Health and Welfare Cat. No. HSE101. Canberra: Australian Institute of Health and Welfare, 2005.
3. McIntyre P, Gidding H, Gilmour R, et al. Vaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000. Commun Dis Intell 2002;26 Suppl:i–111.
4. Brotherton J, McIntyre P, Puech M, et al. Vaccine preventable diseases and vaccination coverage in Australia, 2001 to 2002. Commun Dis Intell 2004;28 Suppl 1:S1–S116.
5. Brotherton J, Wang H, Schaffer A, et al. Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005. Commun Dis Intell 2007;31 Suppl 1:viii–S152.
6. Australian Bureau of Statistics, Australian Institute of Health and Welfare. The health and welfare of Australia’s Aboriginal and Torres Strait Islander peoples: 2001. Cat. No. 4704.0. Canberra: Australian Bureau of Statistics, 2001.
7. Australian Bureau of Statistics, Australian Institute of Health and Welfare. The health and welfare of Australia’s Aboriginal and Torres Strait Islander peoples: 2003. Cat. No. 4704.0. Canberra: Australian Bureau of Statistics, 2003.
8. Australian Bureau of Statistics, Australian Institute of Health and Welfare. The health and welfare of Australia’s Aboriginal and Torres Strait Islander peoples, 2005. Cat. No. 4704.0. Canberra: Australian Bureau of Statistics, 2005.
9. Public Health Committee, National Health and Medical Reasearch Council. Surveillance case definitions. Canberra: Australian Government Printing Service, 1994.
10. Communicable Diseases Network Australia. Interim surveillance case definitions for the Australian National Notifiable Diseases Surveillance System. Version 1. 2004. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/cda_surveil-nndss-dislist.htm/$FILE/casedef.pdf Accessed on 18 May 2007.
11. Owen R, Roche P, Hope K, et al. Australia’s notifiable disease status, 2005: annual report of the National Notifiable Disease Surveillance System. Commun Dis Intell 2007;31:1–70.
12. McIntyre P, Amin J, Gidding H, et al. Vaccine preventable diseases and vaccination coverage in Australia, 1993–1998. Commun Dis Intell 2000;24 Suppl:v–83.
13. Rothman KJ. Modern epidemiology. Boston: Little, Brown and Company, 1986.
14. Draper G, Turrell G, Oldenburg B. Health inequality in Australia: mortality. Health Inequalities Monitoring Series Number 1. AIHW Cat. No. PHE55. Canberra: Queensland University of Technology and Australian Institute of Health and Welfare, 2004.
15. O’Brien ED, Sam GA, Mead C. Methodology for measuring Australia’s childhood immunisation coverage. Commun Dis Intell 1998;22:36–37.
16. Hull BP, McIntyre PB. Immunisation coverage reporting through the Australian Childhood Immunisation Register—an evaluation of the third-dose assumption. Aust N Z J Public Health 2000;24:17–21.
17. Rank C, Menzies RI. How reliable are Australian Childhood Immunisation Register coverage estimates for Indigenous children? An assessment of data quality and coverage. Commun Dis Intell 2007;31:283–287.
18. Vlack SA, Foster R, Menzies R, et al. Immunisation coverage of Queensland Indigenous two year old children by cluster sampling and by register. Aust N Z J Public Health 2007;31:67–72.
19. Australian Bureau of Statistics. National Aboriginal and Torres Strait Islander Health Survey: Users’ Guide, 2004–05. Cat. No. 4715.0.55.004. Canberra: Australian Bureau of Statistics, 2006.
20. National Health and Medical Research Council. The Australian immunisation handbook. 8th ed. Canberra: Australian Government Department of Health and Ageing, 2003.
21. Allen CJ, Ferson MJ. Notification of infectious diseases by general practitioners: a quantitative and qualitative study. Med J Aust 2000;172:325–328.
22. Bonacruz-Kazzi G, McIntyre P, Hanlon M, Menzies R. Diagnostic testing and discharge coding for whooping cough in a children’s hospital. J Paediatr Child Health 2003;39:586–590.
23. Australian Institute of Health and Welfare. Mortality over the twentieth century in Australia: trends and patterns in major causes of death. Mortality Surveillance Series No. 4. Australian Institute of Health and Welfare Cat. No. PHE73. Canberra: Australian Institute of Health and Welfare, 2005.
24. Hull B, Lawrence G, MacIntyre CR, McIntyre P. Immunisation coverage: Australia 2001. Canberra: Commonwealth Department of Health and Ageing, 2002.
25. Skull SA, Andrews RM, Byrnes GB, et al. Validity of self-reported influenza and pneumococcal vaccination status among a cohort of hospitalised elderly patients. Vaccine 2007;25:4775–4783.
26. Ross K. Occasional paper: Population issues, Indigenous Australians, 1996. ABS Cat. No. 4708.0. Canberra: Australian Bureau of Statistics, 1999.
27. Gilbert GL, Clements DA, Broughton SJ. Haemophilus influenzae type b infections in Victoria, Australia, 1985 to 1987. Pediatr Infect Dis J 1990;9:252–257.
28. McIntyre PB, Leeder SR, Irwig LM. Invasive Haemophilus influenzae type b disease in Sydney children 1985–1987: a population-based study. Med J Aust 1991;154:832–837.
29. Hanna J. The epidemiology and prevention of Haemophilus influenzae infections in Australian aboriginal children. J Paediatr Child Health 1992;28:354–361.
30. Horby P, Gilmour R, Wang H, McIntyre P. Progress towards eliminating Hib in Australia: an evaluation of Haemophilus influenzae type b prevention in Australia, 1 July 1993 to 30 June 2000. Commun Dis Intell 2003;27:324–341.
31. Markey P, Krause V, Boslego JW, et al. The effectiveness of Haemophilus influenzae type b conjugate vaccines in a high risk population measured using immunization register data. Epidemiol Infect 2001;126:31–36.
32. Singleton R, Hammit L, Hennessey T, et al. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics 2006;118:e421–e429.
33. Wilson N, Wenger J, Mansoor O, Baker M, Martin D. The beneficial impact of Hib vaccine on disease rates in New Zealand children. N Z Med J 2002;115:U122-U128.
34. Institute of Environmental Science and Research Ltd. Notifiable and other diseases in New Zealand. Annual report 2004. 2005. Available from: http://www.surv.esr.cri.nz/surveillance/annual_surveillance.php Accessed on 20 April 2006.
35. Hull BP, McIntyre PB, Couzos S. Evaluation of immunisation coverage for Aboriginal and Torres Strait Islander children using the Australian Childhood Immunisation Register. Aust N Z J Public Health 2004;28:47–52.
36. Heymann DL, ed. Control of communicable diseases manual. 18th ed. Washington, D.C.: American Public Health Association, 2004.
37. Bell BP, Shapiro C, Alter MJ, et al. The diverse patterns of hepatitis A epidemiology in the United States—implications for vaccination strategies. J Infect Dis 1998;178:1579–1584.
38. Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia: WB Saunders, 2004.
39. Hanna JN, Hills SL, Humphreys JL. Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland. Med J Aust 2004;181:482–485.
40. Minister for Health and Ageing. Government provides free hepatitis A vaccine to Indigenous children. Media release. 2005. Available from: http://www1.health.gov.au/internet/ministers/publishing.nsf/content/health-mediarel-yr2005-ta-abb079.htm/$FILE/abb079.pdf Accessed on 18 May 2007.
41. Bowden FJ, Currie BJ, Miller NC, Locarnini SA, Krause VL. Should aboriginals in the “top end” of the Northern Territory be vaccinated against hepatitis A? Med J Aust 1994;161:372–373.
42. Hanna JN, Warnock TH, Shepherd RW, Selvey LA. Fulminant hepatitis A in indigenous children in north Queensland. Med J Aust 2000;172:19–21.
43. Ferson MJ, Young LC, Stokes ML. Changing epidemiology of hepatitis A in the 1990s in Sydney, Australia. Epidemiol Infect 1998;121:631–636.
44. Amin J, Gilbert GL, Escott RG, Heath TC, Burgess MA. Hepatitis A epidemiology in Australia: national seroprevalence and notifications. Med J Aust 2001;174:338–341.
45. Gilroy NM, Tribe IG, Passaris I, Hall R, Beers MY. Hepatitis A in injecting drug users: a national problem. Med J Aust 2000;172:142–143.
46. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1999;48(RR12):1–37.
47. Kaldor JM, Plant AJ, Thompson SC, Longbottom H, Rowbottom J. The incidence of hepatitis B infection in Australia: an epidemiological review. Med J Aust 1996;165:322–326.
48. Ryder SD, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system: Chronic viral hepatitis. BMJ 2001;322:219–221.
49. O’Sullivan BG, Gidding HF, Law M, et al. Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust N Z J Public Health 2004;28:212–216.
50. Wan X, Mathews JD. Primary hepatocellular carcinoma in Aboriginal Australians. Aust N Z J Public Health 1994;18:286–290.
51. Menzies R, McIntyre P. Vaccine preventable diseases and vaccination policy for indigenous populations. Epidemiol Rev 2006;28:71–80.
52. Williams A. Reduction in the hepatitis B related burden of disease—measuring the success of universal immunisation programs. Commun Dis Intell 2002;26:458–460.
53. Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349–352.
54. Huang K, Lin S. Nationwide vaccination: a success story in Taiwan. Vaccine 2000;18 Suppl 1:S35–S38.
55. Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone, 2000.
56. National Health and Medical Research Council. The Australian immunisation handbook. 7th ed. Canberra: Australian Government Printing Service, 1999.
57. National Health and Medical Research Council. The Australian immunisation handbook. 9th ed. Canberra: Australian Government Department of Health and Ageing, 2008.
58. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232–239.
59. Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule—United States, 2006. MMWR Morb Mortal Wkly Rep 2006;54:Q1–Q4.
60. National Advisory Committee on Immunization. Statement on influenza vaccination for the 2004–2005 season. Can Commun Dis Rep 2004;30 ACS–3:1–32.
61. Patel M, Lush D. Measles vaccine effectiveness in central Australian aboriginal children vaccinated at or after eight months of age. Aust N Z J Public Health 1998;22:729–730.
62. Miller N. Changes to the Northern Territory childhood vaccination schedule—MMR. The Northern Territory Disease Control Bulletin 1998;5:1–2.
63. Turnbull FM, Burgess MA, McIntyre PB, et al. The Australian Measles Control Campaign, 1998. Bull World Health Organ 2001;79:882–888.
64. Patel M. Meningococcal disease in Australia; looking at the past, thinking of the future. Commun Dis Intell 1997;21:233–236.
65. Patel MS, Merianos A, Hanna JN, et al. Epidemic meningococcal meningitis in central Australia, 1987–1991. Med J Aust 1993;158:336–340.
66. Pearce MC, Sheridan JW, Jones DM, et al. Control of group C meningococcal disease in Australian aboriginal children by mass rifampicin chemoprophylaxis and vaccination. Lancet 1995;346:20–23.
67. Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991–2000. J Paediatr Child Health 2001;37:S13–S19.
68. Baker M, McNicholas A, Garrett N, et al. Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. Pediatr Infect Dis J 2000;19:983–990.
69. Thorton V, Lennon D, Rasanathan K, et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 2006;24:1395–1400.
70. Borrow R, Carlone GM, Rosenstein N. Neisseria meningitidis group B correlates of protection and assay standardization—international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. Vaccine 2006;24:5093–5107.
71. Kolos V, Menzies R, McIntyre P. Higher pertussis hospitalization rates in indigenous Australian infants, and delayed vaccination. Vaccine 2007;25:588–590.
72. Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone, 2005.
73. Roche P, Krause V. Invasive pneumococcal disease in Australia, 2001. Commun Dis Intell 2002;26:505–519.
74. Roche P, Krause V, Andrews R, et al. Invasive pneumococcal disease in Australia, 2002. Commun Dis Intell 2003;27:466–477.
75. Roche P, Krause V, Bartlett M, et al. Invasive pneumococcal disease in Australia, 2003. Commun Dis Intell 2004;28:441–454.
76. Roche P, Krause V, Bartlett M, et al. Invasive pneumococcal disease in Australia, 2004. Commun Dis Intell 2006;30:80–92.
77. Roche P, Krause V, Cook H. Invasive pneumococcal disease in Australia, 2005. Commun Dis Intell 2007;31:86–100.
78. Hull BP, McIntyre PB. What do we know about 7vPCV coverage in Aboriginal and Torres Strait Islander children? Commun Dis Intell 2004;28:238–243.
79. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367:740–748.
80. Scott DA, Komjathy SF, Hu BT, et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2007;25:6164–6166.
81. Hanna J, Humphreys JL, Murphy DM. Invasive pneumococcal disease in Indigenous people in north Queensland, 1999–2004. Med J Aust 2006;184:118–121.
82. Mak DB. Invasive pneumococcal disease in the Kimberley, 1995–2001. Aust J Rural Health 2004;12:237–240.
83. Krause V, Cook H, Selvey CE. Impact of 7vPCV and 23vPPV booster in eligible children in the Northern Territory of Australia: impressive, but not the total answer. 5th International Symposium on Pneumococci and Pneumococcal Diseases, Alice Springs, April 2006.
84. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2007;2008, Issue 1:Art. No.: CD000422. DOI: 10.1002/14651858.CD000422.pub2.
85. O’Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007;7:597–606.
86. Preblud SR, Orenstein WA, Bart KJ. Varicella: clinical manifestations, epidemiology and health impact in children. Pediatr Infect Dis 1984;3:505–509.
87. Gidding HF, MacIntyre CR, Burgess MA, Gilbert GL. The seroepidemiology and transmission dynamics of varicella in Australia. Epidemiol Infect 2003;131:1085–1089.
88. Guess HA, Broughton DD, Melton LJ, III, Kurland LT. Population-based studies of varicella complications. Pediatrics 1986;78:723–727.
89. Brody MB, Moyer D. Varicella-zoster virus infection: the complex prevention-treatment picture. Postgrad Med 1997;102:187–190,192–194.
90. Communicable disease surveillance: highlights for 3rd quarter 2006. Commun Dis Intell 2007;30:471–476.
91. Boughton CR. Smallpox and Australia. Intern Med J 2002;32:59–61.
92. Hanna JN. The epidemiology of invasive Haemophilus influenzae infections in children under five years of age in the Northern Territory: a three year study. Med J Aust 1990;152:234–240.
93. Degani N, Navarro C, Deeks S, Lovgren M. Invasive bacterial diseases in northern Canada. Emerg Infect Dis 2008;14:34–40.
94. Krause VL, Reid SJ, Merianos A. Invasive pneumococcal disease in the Northern Territory of Australia, 1994–1998. Med J Aust 2000;173 Suppl:S27–S31.
95. Torzillo PJ, Hanna J, Morey F, et al. Invasive pneumococcal disease in central Australia. Med J Aust 1995;162:182–186.
96. Singleton RJ, Hennessey T, Bulkow L, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007;297:1784–1792.
97. Hanna JN, McCall B, Murphy D. Invasive meningococcal disease in north Queensland, 1990–1994. Commun Dis Intell 1996;20:320–324.
98. Skull SA. A review of national notifiable disease case definitions [report to Communicable Diseases Network Australia New Zealand]. January 2001.
99. O’Grady KA, Counahan M, Birbilis E, Tallis G, eds. Surveillance of notifiable infectious diseases Victoria. Melbourne: Communicable Diseases Section, Rural and Regional Health and Aged Care Service, Victoria Department of Human Services, 2003.
100. Guy RJ, Andrews RM, Kelly HA, et al. Mumps and rubella: a year of enhanced surveillance and laboratory testing. Epidemiol Infect 2004;132:391–398.
This publication is available as a downloadable document.